MX2023005219A - Formulacion solida. - Google Patents

Formulacion solida.

Info

Publication number
MX2023005219A
MX2023005219A MX2023005219A MX2023005219A MX2023005219A MX 2023005219 A MX2023005219 A MX 2023005219A MX 2023005219 A MX2023005219 A MX 2023005219A MX 2023005219 A MX2023005219 A MX 2023005219A MX 2023005219 A MX2023005219 A MX 2023005219A
Authority
MX
Mexico
Prior art keywords
solid formulation
viral replication
pharmaceutical formulations
active pharmaceutical
pharmaceutical ingredient
Prior art date
Application number
MX2023005219A
Other languages
English (en)
Inventor
Donghua Zhu
Kristof Leonard Kimpe
Sune Klint Andersen
Matthieu Jean M Ravelingien
Ivan Henri M Somers
Original Assignee
Janssen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceuticals Inc filed Critical Janssen Pharmaceuticals Inc
Publication of MX2023005219A publication Critical patent/MX2023005219A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se relaciona con formulaciones farmacéuticas que comprenden un ingrediente farmacéutico activo; y uno o una combinación de copolímero de ácido metacrílico, o un derivado de celulosa en donde el ingrediente farmacéutico activo es un inhibidor de la replicación viral del dengue. También se describen formas de dosificación sólidas que comprenden dichas formulaciones farmacéuticas, procesos para prepararlas y suR uso en métodos de prevención y/o tratamiento y/o inhibición de la replicación viral.
MX2023005219A 2020-11-04 2021-11-03 Formulacion solida. MX2023005219A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2020/126596 WO2022094816A1 (en) 2020-11-04 2020-11-04 Solid formulation
PCT/CN2021/128521 WO2022095913A1 (en) 2020-11-04 2021-11-03 Solid formulation

Publications (1)

Publication Number Publication Date
MX2023005219A true MX2023005219A (es) 2023-07-25

Family

ID=78649077

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023005219A MX2023005219A (es) 2020-11-04 2021-11-03 Formulacion solida.

Country Status (15)

Country Link
US (1) US20240000749A1 (es)
EP (1) EP4240331A1 (es)
JP (1) JP2023548348A (es)
KR (1) KR20230104226A (es)
CN (1) CN116685317A (es)
AU (1) AU2021376584A1 (es)
CA (1) CA3200538A1 (es)
CO (1) CO2023005726A2 (es)
CR (1) CR20230192A (es)
DO (1) DOP2023000084A (es)
MX (1) MX2023005219A (es)
PE (1) PE20231946A1 (es)
TW (1) TW202233178A (es)
UY (1) UY39503A (es)
WO (2) WO2022094816A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202428307A (zh) * 2022-10-12 2024-07-16 日商中外製藥股份有限公司 包含胜肽、界面活性劑及聚合物的組成物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2935307C (en) * 2013-12-31 2023-05-09 Ascendia Pharmaceuticals, Llc Pharmaceutical compositions for poorly water-soluble compounds
JOP20160086B1 (ar) * 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
EP3305289A1 (en) * 2016-10-06 2018-04-11 Philipps-Universität Marburg Usage of silvestrol, episilvestrol and silvestrol analoga for the treatment of viral infections caused by viruses with cap-dependent translation
KR102295179B1 (ko) * 2017-09-14 2021-08-30 피닉스 바이오테크놀러지 인코포레이티드. 바이러스 감염 치료를 위한 방법 및 조성물
US20190365738A1 (en) * 2018-05-21 2019-12-05 Cadila Healthcare Limited Amorphous solid dispersion of valbenazine tosylate and process for preparation thereof
EP3852749A4 (en) * 2018-09-18 2022-08-24 Metacrine, Inc. CRYSTALLINE FORMS OF A FARNESOID X RECEPTOR AGONIST
KR102173092B1 (ko) * 2018-11-20 2020-11-02 중앙대학교 산학협력단 루테인 장용성 고체분산체를 유효성분으로 함유하는 위산보호용 조성물 및 이를 포함하는 경구용 제제
CN111407728B (zh) * 2020-04-16 2022-02-22 重庆市畜牧科学院 一种替米考星肠溶性固体分散体及其制备方法和应用

Also Published As

Publication number Publication date
DOP2023000084A (es) 2023-11-15
CR20230192A (es) 2023-10-26
UY39503A (es) 2022-05-31
EP4240331A1 (en) 2023-09-13
US20240000749A1 (en) 2024-01-04
WO2022095913A1 (en) 2022-05-12
WO2022094816A1 (en) 2022-05-12
AU2021376584A1 (en) 2023-06-29
JP2023548348A (ja) 2023-11-16
CA3200538A1 (en) 2022-05-12
CN116685317A (zh) 2023-09-01
KR20230104226A (ko) 2023-07-07
CO2023005726A2 (es) 2023-05-29
TW202233178A (zh) 2022-09-01
PE20231946A1 (es) 2023-12-05

Similar Documents

Publication Publication Date Title
HRP20211543T1 (hr) Derivati kinazolina koji se koriste za liječenje hiv-a
PH12019502577A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
JOP20180025B1 (ar) مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
NO20080284L (no) Cannabionoid aktiv farmasoytisk ingrediens for forbedrede doseringsformer
PH12019502095A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
WO2021168483A3 (en) Treatment of human coronavirus infections using alpha-glucosidase glycoprotein processing inhibitors
PH12019502559A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
WO2019244066A3 (en) Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
WO2006044968A3 (en) Combination therapy for treating viral infections
WO2021232067A8 (en) Stat3 inhibition for treatment and prevention of human coronavirus infection
MX2021010144A (es) Formulaciones farmaceuticas.
MX2023005219A (es) Formulacion solida.
MX2021009219A (es) Triamtereno o nolatrexed para su uso en el tratamiento de la fenilcetonuria.
WO2016090107A3 (en) Treatment of hepatitis delta virus infection
MX2017005163A (es) Composiciones de liberación prolongada de onapristona y métodos.
MX2022005388A (es) Compuestos de pirrolidina y piperidina.
HRP20201436T1 (hr) Makrogoli za davanje na sluznicu i njihove terapeutske primjene
EA201992826A1 (ru) 15бета-[3-пропанамидо]-замещенные эстра-1,3,5(10)-триен-17-оны и их 17-оксимы для применения в ингибировании 17бета-гидроксистероиддегидрогеназ
EP3973976A4 (en) PHARMACEUTICAL COMPOSITION CONTAINING AN EXTRACT OF CAMELLIA JAPONICA AS ACTIVE PRINCIPAL FOR THE PREVENTION AND TREATMENT OF VIRAL INFECTIONS
FI3600276T3 (fi) Betahistiini tai sen farmaseuttisesti hyväksyttävä suola ja monoamiinioksidaasin inhibiittori käytettäväksi yhden tai useamman huimausoireen hoitamisessa tai ehkäisemisessä kohteessa
MX2022000663A (es) Formulaciones farmaceuticas que contienen gaboxadol para tratamiento terapeutico.
JPWO2021060425A5 (es)
EA202191531A1 (ru) Терапевтически активные стероидные производные
MX2024004372A (es) Formulacion oral.
EA202000248A1 (ru) ПРОТИВО-SARS-CoV-2 ВИРУСНОЕ СРЕДСТВО АНТИПРОВИР